Table A3.
Univariate Cox proportional hazards regression analysis to identify the relationship between metastatic sites and survival in patients with stage IV lung cancer harboring rare mutations receiving first-line TKIs.
| Metastatic Site | Progression-Free Survival | Overall Survival | ||
|---|---|---|---|---|
| HR [95% CI] | p Value | HR [95% CI] | p Value | |
| Brain | 1.68 [0.77–3.67] | 0.1902 | 3.82 [1.57–9.26] | 0.0030 |
| Leptomeningeal | 4.23 [0.97–18.38] | 0.0545 | 15.09 [3.02–75.30] | 0.0009 |
| Lung | 1.03 [0.56–1.9] | 0.9202 | 0.63 [0.31–1.30] | 0.2145 |
| Bone | 1.78 [0.97–3.29] | 0.0638 | 1.29 [0.67–2.47] | 0.4440 |
| Pleural | 1.35 [0.75–2.44] | 0.3112 | 1.26 [0.66–2.39] | 0.4816 |
| Pericardial | 0.94 [0.33–2.64] | 0.9021 | 1.01 [0.31–3.30] | 0.9931 |
| Liver | 1.73 [0.75–3.97] | 0.1956 | 1.53 [0.58–4.04] | 0.3885 |
| Adrenal | 0.5 [0.15–1.66] | 0.2565 | 0.36 [0.08–1.51] | 0.1621 |
Abbreviation: HR = hazard ratio; CI = confidence interval.